27
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Phenotypical and functional alteration of unconventional T cells in severe COVID-19 patients

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This study reveals profound alteration in biology of blood unconventional T cells (MAIT, iNKT, and γδT) in severe COVID-19. Highly activated MAIT cells are found in abundance in the airways of mechanically ventilated patients. Activation levels of MAIT/iNKT cells at admission positively correlate with clinical improvement.

          Abstract

          COVID-19 includes lung infection ranging from mild pneumonia to life-threatening acute respiratory distress syndrome (ARDS). Dysregulated host immune response in the lung is a key feature in ARDS pathophysiology. However, cellular actors involved in COVID-19–driven ARDS are poorly understood. Here, in blood and airways of severe COVID-19 patients, we serially analyzed unconventional T cells, a heterogeneous class of T lymphocytes (MAIT, γδT, and iNKT cells) with potent antimicrobial and regulatory functions. Circulating unconventional T cells of COVID-19 patients presented with a profound and persistent phenotypic alteration. In the airways, highly activated unconventional T cells were detected, suggesting a potential contribution in the regulation of local inflammation. Finally, expression of the CD69 activation marker on blood iNKT and MAIT cells of COVID-19 patients on admission was predictive of clinical course and disease severity. Thus, COVID-19 patients present with an altered unconventional T cell biology, and further investigations will be required to precisely assess their functions during SARS–CoV-2–driven ARDS.

          Graphical Abstract

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

          Summary Background Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clinical course of illness, including viral shedding, have not been well described. Methods In this retrospective, multicentre cohort study, we included all adult inpatients (≥18 years old) with laboratory-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) who had been discharged or had died by Jan 31, 2020. Demographic, clinical, treatment, and laboratory data, including serial samples for viral RNA detection, were extracted from electronic medical records and compared between survivors and non-survivors. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death. Findings 191 patients (135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital) were included in this study, of whom 137 were discharged and 54 died in hospital. 91 (48%) patients had a comorbidity, with hypertension being the most common (58 [30%] patients), followed by diabetes (36 [19%] patients) and coronary heart disease (15 [8%] patients). Multivariable regression showed increasing odds of in-hospital death associated with older age (odds ratio 1·10, 95% CI 1·03–1·17, per year increase; p=0·0043), higher Sequential Organ Failure Assessment (SOFA) score (5·65, 2·61–12·23; p<0·0001), and d-dimer greater than 1 μg/mL (18·42, 2·64–128·55; p=0·0033) on admission. Median duration of viral shedding was 20·0 days (IQR 17·0–24·0) in survivors, but SARS-CoV-2 was detectable until death in non-survivors. The longest observed duration of viral shedding in survivors was 37 days. Interpretation The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 μg/mL could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future. Funding Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences; National Science Grant for Distinguished Young Scholars; National Key Research and Development Program of China; The Beijing Science and Technology Project; and Major Projects of National Science and Technology on New Drug Creation and Development.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            COVID-19: consider cytokine storm syndromes and immunosuppression

            As of March 12, 2020, coronavirus disease 2019 (COVID-19) has been confirmed in 125 048 people worldwide, carrying a mortality of approximately 3·7%, 1 compared with a mortality rate of less than 1% from influenza. There is an urgent need for effective treatment. Current focus has been on the development of novel therapeutics, including antivirals and vaccines. Accumulating evidence suggests that a subgroup of patients with severe COVID-19 might have a cytokine storm syndrome. We recommend identification and treatment of hyperinflammation using existing, approved therapies with proven safety profiles to address the immediate need to reduce the rising mortality. Current management of COVID-19 is supportive, and respiratory failure from acute respiratory distress syndrome (ARDS) is the leading cause of mortality. 2 Secondary haemophagocytic lymphohistiocytosis (sHLH) is an under-recognised, hyperinflammatory syndrome characterised by a fulminant and fatal hypercytokinaemia with multiorgan failure. In adults, sHLH is most commonly triggered by viral infections 3 and occurs in 3·7–4·3% of sepsis cases. 4 Cardinal features of sHLH include unremitting fever, cytopenias, and hyperferritinaemia; pulmonary involvement (including ARDS) occurs in approximately 50% of patients. 5 A cytokine profile resembling sHLH is associated with COVID-19 disease severity, characterised by increased interleukin (IL)-2, IL-7, granulocyte-colony stimulating factor, interferon-γ inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1-α, and tumour necrosis factor-α. 6 Predictors of fatality from a recent retrospective, multicentre study of 150 confirmed COVID-19 cases in Wuhan, China, included elevated ferritin (mean 1297·6 ng/ml in non-survivors vs 614·0 ng/ml in survivors; p 39·4°C 49 Organomegaly None 0 Hepatomegaly or splenomegaly 23 Hepatomegaly and splenomegaly 38 Number of cytopenias * One lineage 0 Two lineages 24 Three lineages 34 Triglycerides (mmol/L) 4·0 mmol/L 64 Fibrinogen (g/L) >2·5 g/L 0 ≤2·5 g/L 30 Ferritin ng/ml 6000 ng/ml 50 Serum aspartate aminotransferase <30 IU/L 0 ≥30 IU/L 19 Haemophagocytosis on bone marrow aspirate No 0 Yes 35 Known immunosuppression † No 0 Yes 18 The Hscore 11 generates a probability for the presence of secondary HLH. HScores greater than 169 are 93% sensitive and 86% specific for HLH. Note that bone marrow haemophagocytosis is not mandatory for a diagnosis of HLH. HScores can be calculated using an online HScore calculator. 11 HLH=haemophagocytic lymphohistiocytosis. * Defined as either haemoglobin concentration of 9·2 g/dL or less (≤5·71 mmol/L), a white blood cell count of 5000 white blood cells per mm3 or less, or platelet count of 110 000 platelets per mm3 or less, or all of these criteria combined. † HIV positive or receiving longterm immunosuppressive therapy (ie, glucocorticoids, cyclosporine, azathioprine).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Clinical and immunologic features in severe and moderate Coronavirus Disease 2019

              Journal of Clinical Investigation
                Bookmark

                Author and article information

                Contributors
                Role: ConceptualizationRole: Data curationRole: Formal analysisRole: Funding acquisitionRole: InvestigationRole: MethodologyRole: Project administrationRole: ResourcesRole: SupervisionRole: ValidationRole: VisualizationRole: Writing - original draftRole: Writing - review & editing
                Role: ConceptualizationRole: Data curationRole: Funding acquisitionRole: InvestigationRole: MethodologyRole: Project administrationRole: ResourcesRole: SupervisionRole: ValidationRole: VisualizationRole: Writing - original draftRole: Writing - review & editing
                Role: Investigation
                Role: ConceptualizationRole: Formal analysisRole: InvestigationRole: Resources
                Role: Investigation
                Role: InvestigationRole: Writing - review & editing
                Role: Data curationRole: ValidationRole: Writing - review & editing
                Role: Data curationRole: Writing - review & editing
                Role: ResourcesRole: Validation
                Role: Investigation
                Role: Funding acquisitionRole: ResourcesRole: SupervisionRole: Writing - review & editing
                Role: Project administrationRole: Writing - original draftRole: Writing - review & editing
                Role: ConceptualizationRole: Formal analysisRole: SupervisionRole: Writing - original draftRole: Writing - review & editing
                Role: ConceptualizationRole: Formal analysisRole: Funding acquisitionRole: InvestigationRole: Project administrationRole: SupervisionRole: ValidationRole: VisualizationRole: Writing - original draftRole: Writing - review & editing
                Journal
                J Exp Med
                J. Exp. Med
                jem
                The Journal of Experimental Medicine
                Rockefeller University Press
                0022-1007
                1540-9538
                07 December 2020
                04 September 2020
                04 September 2020
                : 217
                : 12
                : e20200872
                Affiliations
                [1 ]Institut national de la santé et de la recherche médicale, Centre d’Etude des Pathologies Respiratoires, UMR 1100, Tours, France
                [2 ]Université de Tours, Faculté de Médecine de Tours, Tours, France
                [3 ]Service de Médecine Intensive et Réanimation, Centre Hospitalier Régional Universitaire, Tours, France
                [4 ]Service de chirurgie cardiaque et de réanimation chirurgicale cardio-vasculaire, Centre Hospitalier Régional Universitaire, Tours, France
                [5 ]Service de pneumologie, Centre Hospitalier Régional Universitaire, Tours, France
                [6 ]Intensive Care Unit, Dupuytren Teaching Hospital, Limoges, France
                [7 ]Institut national de la santé et de la recherche médicale CIC1435, Dupuytren Teaching Hospital, Limoges, France
                [8 ]Institut national de la santé et de la recherche médicale UMR 1092, University of Limoges, Limoges, France
                Author notes
                Correspondence to Youenn Jouan: youenn.jouan@ 123456chu-tours.fr

                Disclosures: S. Ehrmann reported personal fees from Aerogen, grants from Fisher & Paykel, grants from Hamilton Medical, and personal fees from La Diffusion Technique Française outside the submitted work. M. Si-Tahar reported personal fees from Cynbiose Respiratory outside the submitted work. No other disclosures were reported.

                [*]

                A. Guillon and L. Gonzalez contributed equally to this paper.

                [**]

                T. Baranek and C. Paget contributed equally to this paper.

                Author information
                https://orcid.org/0000-0002-9844-814X
                https://orcid.org/0000-0002-4884-8620
                https://orcid.org/0000-0002-5708-3332
                https://orcid.org/0000-0003-2083-040X
                https://orcid.org/0000-0002-8106-7009
                https://orcid.org/0000-0001-6221-4467
                https://orcid.org/0000-0001-6311-0256
                https://orcid.org/0000-0002-3474-7247
                https://orcid.org/0000-0002-5170-736X
                https://orcid.org/0000-0002-9777-1797
                https://orcid.org/0000-0003-4819-1769
                https://orcid.org/0000-0002-5792-7742
                https://orcid.org/0000-0002-5651-0937
                https://orcid.org/0000-0002-5374-5407
                Article
                jem.20200872
                10.1084/jem.20200872
                7472174
                32886755
                b5efbe4b-0ac6-4dd1-9352-9450d5c1f2ec
                © 2020 Jouan et al.

                This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

                History
                : 05 May 2020
                : 24 June 2020
                : 12 August 2020
                Page count
                Pages: 9
                Funding
                Funded by: Agence Nationale de la Recherche, DOI http://dx.doi.org/10.13039/501100001665;
                Award ID: ANR-19-CE15-0032-01
                Funded by: Fondation du Souffle, DOI http://dx.doi.org/10.13039/100012019;
                Funded by: Fonds de Recherche en Santé Respiratoire, DOI http://dx.doi.org/10.13039/501100010482;
                Funded by: Institut national de la santé et de la recherche médicale, DOI http://dx.doi.org/10.13039/501100001677;
                Funded by: Centre Hospitalier Régional Universitaire de Tours;
                Funded by: University of Tours, DOI http://dx.doi.org/10.13039/501100007526;
                Categories
                Brief Definitive Report
                Mucosal Immunology
                Innate Immunity and Inflammation
                Infectious Disease and Host Defense

                Medicine
                Medicine

                Comments

                Comment on this article